Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer
暂无分享,去创建一个
[1] J. C. Love,et al. Mitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations , 2022, Nature Biotechnology.
[2] James M. McFarland,et al. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer , 2021, Cell.
[3] X. Zhang,et al. Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers , 2021, Science Translational Medicine.
[4] J. Lohr,et al. Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma , 2021, Nature Cell Biology.
[5] Jeffrey J. Quinn,et al. Lineage Recording Reveals the Phylodynamics, Plasticity and Paths of Tumor Evolution , 2021, bioRxiv.
[6] Z. Modrušan,et al. Identifying transcriptional programs underlying cancer drug response with TraCe-seq , 2021, Nature Biotechnology.
[7] A. Regev,et al. Cycling cancer persister cells arise from lineages with distinct programs , 2021, Nature.
[8] Kaitlyn E. Johnson,et al. Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment , 2021, Nature Cancer.
[9] L. Zhong,et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives , 2021, Signal Transduction and Targeted Therapy.
[10] Xiaohui S. Xie,et al. Lineage tracing and analog recording in mammalian cells by single-site DNA writing , 2021, Nature Chemical Biology.
[11] Jeffrey J. Quinn,et al. Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts , 2020, Science.
[12] Sydney M. Shaffer,et al. Variability within rare cell states enables multiple paths towards drug resistance , 2020, Nature Biotechnology.
[13] Kirsten L. Frieda,et al. Imaging cell lineage with a synthetic digital recording system , 2020, Science.
[14] S. Konermann,et al. CloneSifter: enrichment of rare clones from heterogeneous cell populations , 2020, BMC biology.
[15] Samantha A. Morris,et al. Next-Generation Lineage Tracing and Fate Mapping to Interrogate Development. , 2020, Developmental cell.
[16] S. Dawson,et al. Non-genetic mechanisms of therapeutic resistance in cancer , 2020, Nature Reviews Cancer.
[17] D. Landau,et al. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics , 2020, Nature Reviews Genetics.
[18] R. Cantón,et al. Collateral sensitivity associated with antibiotic resistance plasmids , 2020, bioRxiv.
[19] C. Coman,et al. A multi-omics analysis reveals the unfolded protein response regulon and stress-induced resistance to folate-based antimetabolites , 2020, Nature Communications.
[20] S. Orkin,et al. An Engineered CRISPR-Cas9 Mouse Line for Simultaneous Readout of Lineage Histories and Gene Expression Profiles in Single Cells , 2020, Cell.
[21] Mateusz Kciuk,et al. Mechanisms of Multidrug Resistance in Cancer Chemotherapy , 2020, International journal of molecular sciences.
[22] J. Wilmott,et al. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition , 2020, Nature Communications.
[23] K. Polyak,et al. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. , 2020, Cancer cell.
[24] Lin Tang. Integrating lineage tracing and single-cell analysis , 2020, Nature Methods.
[25] Amy E. Decker,et al. Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer , 2020, Nature Genetics.
[26] H. Ouzon-Shubeita,et al. Structural insights into the promutagenic bypass of the major cisplatin-induced DNA lesion. , 2020, The Biochemical journal.
[27] T. Stankovic,et al. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial , 2020, Leukemia.
[28] Einar Bjarki Gunnarsson,et al. Understanding the role of phenotypic switching in cancer drug resistance. , 2020, Journal of theoretical biology.
[29] Allon M. Klein,et al. Lineage tracing on transcriptional landscapes links state to fate during differentiation , 2018, Science.
[30] Charles C. Bell,et al. Principles and mechanisms of non-genetic resistance in cancer , 2019, British Journal of Cancer.
[31] Catherine J. Wu,et al. Clonal dynamics in chronic lymphocytic leukemia. , 2019, Blood advances.
[32] Mark W. Budde,et al. In situ readout of DNA barcodes and single base edits facilitated by in vitro transcription , 2019, Nature Biotechnology.
[33] A. Bardelli,et al. Adaptive mutability of colorectal cancers in response to targeted therapies , 2019, Science.
[34] Mariella G. Filbin,et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma , 2019, Cell.
[35] J. Ursini-Siegel,et al. An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy , 2019, Nature Communications.
[36] Samantha A. Morris,et al. CellTag Indexing: genetic barcode-based sample multiplexing for single-cell genomics , 2019, Genome Biology.
[37] Martin J. Aryee,et al. Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics , 2019, Cell.
[38] Jacob G. Scott,et al. Resistance to ALK targeting therapies as a gradual Darwinian adaptation to inhibitor specific selective pressures , 2018, bioRxiv.
[39] Howard Y. Chang,et al. Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA , 2018, bioRxiv.
[40] L. Galluzzi,et al. Linking cellular stress responses to systemic homeostasis , 2018, Nature Reviews Molecular Cell Biology.
[41] Evert Bosdriesz,et al. An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential , 2018, Cell.
[42] Wei Cheng,et al. New insights from the widening homogeneity perspective to target intratumor heterogeneity , 2018, Cancer communications.
[43] G. Mayhew,et al. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal , 2018, Cell.
[44] Mi Ni Huang,et al. In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors , 2017, bioRxiv.
[45] James A. Gagnon,et al. Simultaneous single-cell profiling of lineages and cell types in the vertebrate brain , 2018, Nature Biotechnology.
[46] J. Balko,et al. TGF-b inhibition enhances chemotherapy action against triple-negative breast cancer , 2018 .
[47] Jason W. Locasale,et al. Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. , 2017, Cell reports.
[48] D. Wheeler,et al. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. , 2017, European urology.
[49] Wei Chen,et al. Polylox barcoding reveals haematopoietic stem cell fates realized in vivo , 2017, Nature.
[50] William A. Flavahan,et al. Epigenetic plasticity and the hallmarks of cancer , 2017, Science.
[51] G. Mills,et al. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers , 2017, Science Translational Medicine.
[52] Jacob G. Scott,et al. Somatic clonal evolution: A selection-centric perspective. , 2017, Biochimica et biophysica acta. Reviews on cancer.
[53] Nicholas Navin,et al. Tumor evolution: Linear, branching, neutral or punctuated? , 2017, Biochimica et biophysica acta. Reviews on cancer.
[54] N. McGranahan,et al. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.
[55] Davide Prandi,et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma , 2016, Nature Genetics.
[56] Sue Chua,et al. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. , 2016, Cancer discovery.
[57] Gábor E. Tusnády,et al. A comprehensive survey of the mutagenic impact of common cancer cytotoxics , 2016, Genome Biology.
[58] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[59] Raja R Srinivas,et al. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution , 2016, Cell.
[60] G. Getz,et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.
[61] G. Getz,et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. , 2016, The New England journal of medicine.
[62] Hanlee P. Ji,et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.
[63] Xuemei Lu,et al. Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution , 2015, Proceedings of the National Academy of Sciences.
[64] Martin A. Nowak,et al. Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.
[65] M. Ibrahim,et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp , 2015, Cancer Cell International.
[66] Charles Swanton,et al. Clinical management of breast cancer heterogeneity , 2015, Nature Reviews Clinical Oncology.
[67] A. Pisco,et al. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me' , 2015, British Journal of Cancer.
[68] Joshua M. Korn,et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding , 2015, Nature Medicine.
[69] Andrei Kucharavy,et al. Targeting the Adaptability of Heterogeneous Aneuploids , 2015, Cell.
[70] P. Majumder,et al. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.
[71] C. Curtis,et al. A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.
[72] Evis Sala,et al. Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis , 2015, PLoS medicine.
[73] H P Soyer,et al. A stress-induced early innate response causes multidrug tolerance in melanoma , 2014, Oncogene.
[74] Yu Cao,et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.
[75] Luca Magnani,et al. Poised epigenetic states and acquired drug resistance in cancer , 2014, Nature Reviews Cancer.
[76] Samra Turajlic,et al. BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling , 2014, Science Signaling.
[77] C. Sander,et al. Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy , 2014, Clinical Cancer Research.
[78] A. McKenna,et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.
[79] Steven J. M. Jones,et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.
[80] K. Robasky,et al. The role of replicates for error mitigation in next-generation sequencing , 2013, Nature Reviews Genetics.
[81] K. Cimprich,et al. Causes and consequences of replication stress , 2013, Nature Cell Biology.
[82] L. Cantley,et al. What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. , 2013, Cancer discovery.
[83] Amy Brock,et al. Non-Darwinian dynamics in therapy-induced cancer drug resistance , 2013, Nature Communications.
[84] C. Zahnow,et al. The future of epigenetic therapy in solid tumours—lessons from the past , 2013, Nature Reviews Clinical Oncology.
[85] E. Mroz,et al. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. , 2013, Oral oncology.
[86] J. Balko,et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. , 2013, The Journal of clinical investigation.
[87] M. Deininger,et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia , 2012, Nature Reviews Cancer.
[88] Jian Jin,et al. Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.
[89] A. Tolcher,et al. The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.
[90] Carlo C. Maley,et al. Clonal evolution in cancer , 2012, Nature.
[91] E. Lander,et al. Theory Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells , 2011 .
[92] Peter A. Jones,et al. A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.
[93] E. Lander,et al. Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells , 2011, Cell.
[94] Gaetano Rocco,et al. Epithelial to Mesenchymal Transition by TGFβ-1 Induction Increases Stemness Characteristics in Primary Non Small Cell Lung Cancer Cell Line , 2011, PloS one.
[95] P. Ding,et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. , 2010, Leukemia research.
[96] Ling Xia,et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. , 2009, Cancer research.
[97] Laura M. Heiser,et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.
[98] P. Valent. Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches , 2007, Biologics : targets & therapy.
[99] Peter A. Jones,et al. The Epigenomics of Cancer , 2007, Cell.
[100] L. Boise,et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. , 2006, Blood.
[101] I. Christensen,et al. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. , 1997, British Journal of Cancer.
[102] H. Suzuki,et al. Differential induction of chromosomal aberrations by topoisomerase inhibitors in cultured Chinese hamster cells. , 1994, Biological & pharmaceutical bulletin.
[103] B. Hill. Potential of continuous tumour cell lines for establishing patterns of cross-resistance and collateral sensitivity in vitro. , 1986, Drugs under experimental and clinical research.